KatherineBarnettPetersMDPhD FAAN

Neurooncology

Associate Professor, Neurology and Neurosurgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University School of Medicine

Join to view full profile

Dr. Peters is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Peters' full profile

Already have an account?

Office
047 Baker House
Durham, NC 27710
Phone+1 919-684-6173

Education & Training

Johns Hopkins UniversityResidency, Neurology, 2004 - 2007
Johns Hopkins UniversityInternship, Internal Medicine, 2003 - 2004
Stanford University School of MedicineClass of 2003, MD PhD

Certifications & Licensure

NC State Medical License 2008 - 2025
MD State Medical License 2006 - 2011
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas Start of enrollment: 2004 Apr 01
Completed
Phase 1
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas Start of enrollment: 2007 Aug 01
Completed
Phase 2
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas Start of enrollment: 2009 Oct 01
Completed
Phase 1, Phase 2
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Start of enrollment: 2009 Nov 01
Completed
Phase 2
AMG 102 and Avastin for Recurrent Malignant Glioma Start of enrollment: 2010 Aug 01
Completed
Phase 2
Effects of Steroid Tapering on Functional Capacity and Neurocognition Start of enrollment: 2010 Jun 01
Withdrawn
Not Applicable
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Low Dose Naltrexone for Glioma Patients Start of enrollment: 2011 May 01
Completed
Phase 2
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide Start of enrollment: 2014 Jun 24
Completed
Phase 2
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Start of enrollment: 2013 Jan 01
Completed
Phase 2
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment Start of enrollment: 2023 Jun 27
RECRUITING
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Financial toxicity of oral chemotherapy in patients with primary brain tumors.
Mallika P Patel, Mary Lou Affronti, Evan D Buckley, James E Herndon Ii, Emma M Mackowsky
Neuro-Oncology Practice. 2025-02-01
Symptom management in isocitrate dehydrogenase mutant glioma.
Tobias Walbert, Edward K Avila, Florien W Boele, Caroline Hertler, Christine Lu-Emerson
Neuro-Oncology Practice. 2025-02-01
Education Research: Burnout and Perception of Value in a Cross-Section of Neurology Residency Program Directors.
Alissa S Higinbotham, James T Patrie, Katherine B Peters
Neurology. Education. 2024-09-25

Abstracts/Posters

Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation
Katherine B. Peters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Drug Born at Duke Improves Survival in People with Advanced Brain CancerJanuary 20th, 2024

Grant Support

Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 gliomaDUKE UNIVERSITY2022–2026